Danielle Hernandez joined Caris Life Sciences in July 2020, and currently serves as a Molecular Science Liaison for the Midwest’s Great Plains region. She works closely with health care providers, researchers, and oncology leaders to advance the understanding of molecular science and precision medicine, lead molecular tumor boards, and support clinical translational research that integrates molecular tumor profiling and artificial intelligence to drive advancements in precision oncology. Danielle holds a B.S. in Science Education from Northern Michigan University, where she developed her passions for biomedical sciences, patient-driven research, and medical science education, which later led her to the Mayo Clinic where she earned her Ph.D. in biomedical sciences with emphasis in biochemistry, molecular biology, and cancer biology. Notably, prior to joining Caris she completed her post-doctoral training at the University of Minnesota, in the Department of Neurosurgery, where she devised new approaches incorporating advanced genomic technologies, single cell techniques, and protein biochemistry to evaluate brain tumor heterogeneity associated with therapeutic resistance, tumor reoccurrence, and poor prognosis.